Enlivex (ENLV) Depreciation & Amortization (CF) (2014 - 2025)
Enlivex (ENLV) posted quarterly Depreciation & Amortization (CF) of $76000.0 for Q4 2025, up 111.11% year-over-year from $36000.0 in Q4 2024, and down 6.17% quarter-over-quarter from $81000.0 in Q3 2025.
Enlivex (ENLV) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
Enlivex's Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $76000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 111.11% year-over-year to $76000.0; the TTM figure through Dec 2025 stood at $332000.0 (down 39.08% YoY), while the FY2025 annual figure was $332000.0, down 39.08% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $76000.0, down from $81000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $221000.0 in Q4 2022, with the low at $36000.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $160500.0 (2024), against an average of $151750.0.
- The sharpest annual moves came in 2021 and 2024: Depreciation & Amortization (CF) surged 118.06% in 2021, then sank 82.0% in 2024.
- Enlivex's Depreciation & Amortization (CF) stood at $150000.0 in 2021, then surged by 47.33% to $221000.0 in 2022, then decreased by 9.5% to $200000.0 in 2023, then tumbled by 82.0% to $36000.0 in 2024, then jumped by 111.11% to $76000.0 in 2025.
- Business Quant data shows ENLV's Depreciation & Amortization (CF) at $76000.0 in Q4 2025, $81000.0 in Q3 2025, and $85000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 76,000.00 |
| Dec 31, 2025 | 76,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 85,000.00 |
| Mar 31, 2025 | 90,000.00 |
| Mar 31, 2025 | 90,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Sep 30, 2023 | 214,000.00 |